BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang Y, Xie D, Tang N, Wang J, Zeng X, Zhao P, He L. XRCC1 Arg399Gln variation and leukemia susceptibility: evidence from 2,647 cases and 5,518 controls. Tumour Biol 2014;35:799-808. [PMID: 23990457 DOI: 10.1007/s13277-013-1110-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Valikhani M, Rahimian E, Ahmadi SE, Chegeni R, Safa M. Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment. Exp Hematol Oncol 2021;10:51. [PMID: 34732266 DOI: 10.1186/s40164-021-00242-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Rahimian E, Amini A, Alikarami F, Pezeshki SMS, Saki N, Safa M. DNA repair pathways as guardians of the genome: Therapeutic potential and possible prognostic role in hematologic neoplasms. DNA Repair (Amst) 2020;96:102951. [PMID: 32971475 DOI: 10.1016/j.dnarep.2020.102951] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Huang Y, Huang Y, Chang A, Wang J, Zeng X, Wu J. Is Toxoplasma Gondii Infection a Risk Factor for Leukemia? An Evidence-Based Meta-Analysis. Med Sci Monit 2016;22:1547-52. [PMID: 27155015 DOI: 10.12659/msm.897155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
4 Bret C, Viziteu E, Kassambara A, Moreaux J. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy. Expert Rev Hematol 2016;9:351-60. [PMID: 26761438 DOI: 10.1586/17474086.2016.1141673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang F, Zhao Q, He HR, Zhai YJ, Lu J, Hu HB, Zhou JS, Yang YH, Li YJ. The association between XRCC1 Arg399Gln polymorphism and risk of leukemia in different populations: a meta-analysis of case-control studies. Onco Targets Ther 2015;8:3277-87. [PMID: 26609240 DOI: 10.2147/OTT.S92752] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
6 Lu J, Zhao Q, Zhai YJ, He HR, Yang LH, Gao F, Zhou RS, Zheng J, Ma XC. Genetic polymorphisms of CYP1A1 and risk of leukemia: a meta-analysis. Onco Targets Ther. 2015;8:2883-2902. [PMID: 26491362 DOI: 10.2147/ott.s92259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
7 Esposito MT, So CWE. DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance. Chromosoma 2014;123:545-61. [DOI: 10.1007/s00412-014-0482-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]